{"brief_title": "Intramuscular Aripiprazole in Acutely Agitated Patients Diagnosed With Dementia", "brief_summary": "The purpose of this trial is to test the safety & tolerability of intramuscular aripiprazole in acutely agitated patients diagnosed with Dementia.", "condition": ["Dementia", "Alzheimer's Disease"], "intervention_type": ["Drug", "Drug"], "intervention_name": ["Aripiprazole", "Placebo"], "description": ["IM Solution, IM, Cohort 1 - 2.5mg (.33cc) maximum dose 5.0mg; 2 injections 2nd injection 2 hours after first; Cohort 2 - 5.0mg (.67cc) maximum dose 10 mg; 2 injections 2nd injection 2 hours after first; Cohort 3 - 10 mg (1.3cc) or 5.0 mg (.67cc) maximum dose 15mg; 1 injection, 24 hour observation for all cohorts.", "IM Solution, IM, Cohort 1 - 0mg; 2 injections 2nd injection 2 hours after first; Cohort 2 - 0mg; 2 injections 2nd injection 2 hours after first; Cohort 3 - 0mg; 1 injection, 24 hour observation for all cohorts."], "arm_group_label": ["A1", "B1"], "other_name": ["Abilify"], "criteria": "Inclusion Criteria: - Acute agitation in Patients with a DSM-IV diagnosis of Alzheimer's, vascular or mixed Dementia. Exclusion Criteria: - Current DSM-IV Axis 1 diagnosis other than Alzheimer's, vascular or mixed Dementia.", "gender": "All", "minimum_age": "55 Years", "maximum_age": "95 Years", "healthy_volunteers": "No", "keyword": "Acute agitation in patients diagnosed with Dementia", "mesh_term": ["Alzheimer Disease", "Dementia", "Aripiprazole"], "id": "NCT00095719"}